CARLOS
TAXONERA SAMSO
Profesor asociado de Ciencias de la Salud
Hospital General de Ciudad Real
Ciudad Real, EspañaPublications en collaboration avec des chercheurs de Hospital General de Ciudad Real (8)
2022
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
2021
-
Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study
Therapeutic Advances in Gastroenterology, Vol. 14
2020
-
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry
Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616
2018
-
Serial tuberculin skin tests improve the detection of latent tuberculosis infection in patients with inflammatory bowel disease
Journal of Crohn's and Colitis, Vol. 12, Núm. 11, pp. 1270-1279
2017
-
Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study
American Journal of Gastroenterology, Vol. 112, Núm. 1, pp. 120-131